Inflation Hits Cannabis Industry as Prices Rise

Aug.09.2022
Inflation Hits Cannabis Industry as Prices Rise
Inflation is impacting the cannabis industry, with one in four retailers reporting plans to raise prices by over 10%.

Although inflation has already disrupted many people's plans for summer off-road trips, the impact of rising prices could soon cause real harm to certain individuals.


So far, marijuana and many related products have largely shed the double-digit growth seen in many foods, from chicken to avocados. An analysis firm even reported that prices for marijuana flowers, edibles, and vape products fell by 16.7%, 11.8%, and 12.4%, respectively, between January 2021 and 2022.


Due to a variety of interconnected reasons, such as lack of available materials and supply chain disruptions, the prices of most things have been steadily and rapidly increasing at a rate unseen in 40 years. Even if the prices of main products have not risen, the increase in packaging material costs has had little effect on any industry.


From June 2021 to June 2022, the Consumer Price Index has increased 9.1%. Additionally, according to a recent report from the cannabis industry and accounting firm GreenGrowth CPAs, the cannabis industry may finally be experiencing inflation. With labor and material costs for producing ready-to-eat cannabis products on the rise, one in four cannabis retailers report that they have already increased or plan to increase prices by 10% or more next year.


According to the report, the impact of the COVID-19 pandemic on cannabis businesses has been relatively limited. Based on last year's data, supply chain and recruitment difficulties were reported as issues affecting almost all industries in 2021, in addition to supply challenges being the most common issue currently impacting operators. The survey examined over 700 companies in states where recreational or medical cannabis use is legal, including startups and large multinational operators. While 70% of operators reported they would attempt to absorb rising costs rather than raise prices, 30% plan to proactively increase prices to prevent losses.


The survey found that there were differing opinions among respondents regarding responsibility for rising inflation, with 40% citing policies of the Biden administration and 30% attributing it to lingering impacts of the Trump administration. Other reasons quoted by operators included supply-chain issues, conflicts with countries like Russia and China, and effects of the oil industry's operations. Nationwide numbers are not entirely reflective as marijuana use and production currently remain illegal at a federal level. However, despite price increases, demand for marijuana has remained strong during and after the COVID-19 outbreak. Since the start of quarantine, some online delivery services in California have seen sales increase by 500%.


After two years of crisis and uncertainty following the global pandemic, cannabis financial operators find themselves navigating a range of new, complex situations and business obstacles," the report states. "But it's not all bad news. Many operators have benefited from the surge in demand and are using this new windfall to develop ambitious growth plans.


Statement


This article is compiled from third-party information and is intended for industry communication and learning purposes only.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is only intended for industry communication and research.


Due to limitations in translation proficiency, the translated article may not fully correspond with the original text. Therefore, the original text should be referred to for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign affairs positions and statements.


The copyright of the compiled information belongs to the original media and author, and if there is any infringement, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts Holds Second PMTA Compliance Training in Shenzhen, Highlighting U.S. Regulatory Framework and Corporate Compliance Capabilities
2Firsts held its second U.S. PMTA compliance training in Shenzhen, providing a systematic overview of the U.S. regulatory framework for e-cigarettes and corporate compliance strategies. Nearly 20 industry professionals from manufacturing, e-liquid and supply-chain companies attended. Participants who passed the exam received compliance certification. Registration for the third training session will open soon, alongside customized corporate training programs.
Mar.09
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Positions VLN® Cigarettes for Growth as FDA Considers 0.7 mg/g Nicotine Cap
22nd Century Group (Nasdaq: XXII) reported early commercial momentum for its FDA-authorized VLN® very low nicotine cigarettes, distributing approximately 8,800 cartons across 1,700 new U.S. retail outlets in the fourth quarter of 2025, while forecasting expansion to more than 5,000 retail points in 2026.
Business
Feb.24
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
Editorial says West Virginia’s HB 5437 “Vape Safety Act” goes too far, targeting residency and citizenship provisions
Editorial says West Virginia’s HB 5437 “Vape Safety Act” goes too far, targeting residency and citizenship provisions
A News and Sentinel editorial argues that West Virginia’s HB 5437, the “Vape Safety Act,” goes beyond reasonable regulation by adding provisions barring any part of a vape or smoke shop from being used as a residence and requiring owners to be U.S. citizens.
Feb.27 by 2FIRSTS.ai
PMI’s Portuguese unit to launch nicotine pouches in 2026 after tax clarification
PMI’s Portuguese unit to launch nicotine pouches in 2026 after tax clarification
After Portugal included nicotine pouches in the excise-tax (IEC) framework for tobacco and nicotine products, PMI’s Portuguese subsidiary Tabaqueira confirmed it will begin selling nicotine pouches in the country this year. The company is preparing a soft launch in two stores ahead of wider distribution, as the tax and regulatory position becomes clearer.
Mar.10 by 2FIRSTS.ai
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
France’s HAS to Address Role of E-Cigarettes in Updated Smoking-Cessation Guidelines, Tells 2Firsts
2Firsts has learned that France’s national health authority, the Haute Autorité de Santé (HAS), confirmed the role of e-cigarettes will be addressed in updated national smoking-cessation guidelines expected by the end of 2026. HAS said the recommendations will focus on clinical and public-health considerations, will not set technical standards for vaping products, and that current studies are insufficient to clearly assess risks and benefits across different product categories.
Mar.10